Taking effect on March 1...Collecting opinions by February 20th
The reimbursement criteria for two doses(25μg, 50μg) of Ferring Pharmaceuticals Korea’s idiopathic nocturnal polyuria treatment, Nocdurna(desmopressin) sublingual tablet, will be established.
The Ministry of Health and Welfare pre-announced an revision notice(Ministry of Health and Welfare Notification No.121, 2020) of ‘Details on the criteria and methods for application of medical care benefit’ and began collecting opinions by February 20 with the aim of implementing it on the March 1.
According to the revision, the reimbursement criteria for Nocdurna sublingual tablet will be added to the reimbursement criteria for existing oral desmopressin formulation.
But the clause related to primary nocturnal enuresis, which is not approved, specified that Nocdurna sublingual tablet is excluded. And, in the clause on nocturia due to nocturnal polyuria, the phrase added ‘only for the treatment of nocturia due to idiopathic nocturnal polyuria’.
Nocdurna sublingual tablet is approved for treatment of adults with nocturia due to idiopathic nocturnal polyuria; 50μg for men once daily at one hour before bedtime, 25μg for women once daily at one hour before bedtime, administered sublingually without water.
Dose escalation is not recommended in older patients over 65 years of age and may be escalated with oral desmopressin if there is insufficient response.
